EDIT - Company ID 0001650664
Editas Medicine, Inc. trades as EDIT. In its fiscal 2025 annual report the company posted revenue of $40.52M, up 25.4% from the prior year and net income of -$160.06M. This page tracks Editas Medicine, Inc. through 693 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Editas Medicine, Inc.'s revenue grew from $6.05M to $40.52M, a compound annual growth rate of 23.5%. Net profit margin expanded from -1605.5% to -395.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Prospectus supplement | 424B5 | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| S-3MEF | - | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| Prospectus supplement | 424B5 | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
| Major company event | 8-K | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-05 |
The largest companies sharing Editas Medicine, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Editas Medicine, Inc. reported revenue of $40.52M for fiscal year 2025, an increase of 25.4% year over year.
In its latest fiscal year Editas Medicine, Inc. reported a net loss of $160.06M.